Jeito Capital
Investor profile
Jeito Capital has backed 10 European tech companies across 12 funding rounds between 2020 and 2025, joining rounds totalling €912M. Most active in Healthtech. Data as of Nov 2026.
Deals
12
distinct rounds
Companies
10
backed
Active span
2020–2025
6 yrs
Total round €
€912M
sum of rounds joined
Deals by year
distinct rounds / yearJeito Capital — deals by year — interactive chart.
Data table
| Jeito Capital — deals by year | |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
Top sectors
by dealsJeito Capital — top sectors — interactive chart.
Data table
| Jeito Capital — top sectors | |
|---|---|
| Healthtech | 12 |
Stages
by dealsJeito Capital — stages — interactive chart.
Data table
| Jeito Capital — stages | |
|---|---|
| Series B | 6 |
| Series A | 3 |
| Other | 2 |
| Series C | 1 |
Countries
by dealsJeito Capital — countries — interactive chart.
Data table
| Jeito Capital — countries | |
|---|---|
| Switzerland | 3 |
| UK | 3 |
| Netherlands | 2 |
| Belgium | 1 |
| Denmark | 1 |
| France | 1 |
| Germany | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Forbion5
- SV Health Investors3
- UPMC Enterprises3
- Gilde Healthcare2
- INKEF Capital2
- Invus2
- MRL Ventures Fund2
- Novo Holdings2
- Polaris Partners2
- Samsara Biocapital2
- Sofinnova Partners2
- Syncona Partners2
- Ysios Capital2
- 4BIO Capital1
- ALSA Ventures1
- AXA IM Alts1
- Bain Capital Life Sciences1
- Bayern Kapital1
- BioGeneration Ventures1
- BioGeneration Ventures (BGV)1
- BioMedPartners1
- Bpifrance1
- Brandon Capital1
- British Patient Capital1
- Coparion1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Quell Therapeutics | UK | 1 | €138M |
| Noema Pharma | Switzerland | 2 | €134M |
| Azafaros | Netherlands | 1 | €132M |
| EyeBiotech | UK | 2 | €118M |
| Neogene Therapeutics | Netherlands | 1 | €93M |
| Precirix | Belgium | 1 | €80M |
| Sparingvision | France | 1 | €75M |
| ReproNovo | Switzerland | 1 | €57M |
| CatalYm | Germany | 1 | €50M |
| NMD Pharma | Denmark | 1 | €35M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Quell Therapeutics | Series B | €138M | 2021-11 |
| Azafaros | Series B | €132M | 2025-05 |
| Noema Pharma | Series B | €105M | 2023-03 |
| Neogene Therapeutics | Other | €93M | 2020-09 |
| Precirix | Series B | €80M | 2022-03 |
| Sparingvision | Series B | €75M | 2022-09 |
| EyeBiotech | Series A | €61M | 2023-11 |
| EyeBiotech | Series A | €57M | 2022-02 |
| ReproNovo | Series A | €57M | 2025-05 |
| CatalYm | Series C | €50M | 2022-11 |